Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim IntfiledCriticalBoehringer Ingelheim Int
Priority to UY27291ApriorityCriticalpatent/UY27291A1/en
Publication of UY27291A1publicationCriticalpatent/UY27291A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
La presente invención se refiere a nuevos conjugados de anticuerpos con compuestos citotóxicos, a composiciones farmacéuticas que contienen dichos conjugados, y a su uso en la terapia del cáncer. En concreto, la presente invención se refiere a conjugados de anticuerpos que son específicos para cd44, con maitansinoides, preferiblemente con N2- desacetil-N2- (3-mercapto-1-oxopropil) maitansina.The present invention relates to new antibody conjugates with cytotoxic compounds, pharmaceutical compositions containing said conjugates, and their use in cancer therapy. Specifically, the present invention relates to antibody conjugates that are specific for cd44, with maitansinoids, preferably with N2-deacetyl-N2- (3-mercapto-1-oxopropyl) maitansin.
UY27291A2002-05-152002-05-15
IMMUNOCONJUGADOS OF CD44 TOXIC ANTIBODIES
UY27291A1
(en)
Antibody that specifically binds to crypto epitope; pharmaceutical composition comprising said antibody; use of the antibody to decrease the growth of a tumor in vitro; method to modulate the growth of tumor cells in vitro in a sample; humanized antibody (div. sol. No. 831-2002).
ANTIBODY CONJUGATE - ASSOCIATED MOLECULA DIRECTED TO THE PROTEIN TIROSINA QUINASA 7 (PTK 7), PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, NUCLEIC ACID, EXPRESSION FACTOR AND RELATED HUMAN CELL AND ITS USE TO PREPARE A MEDICATION
Use of an anti-cd20 type II antibody useful to prepare a drug to treat a cancer that expresses cd20 in combination with a proteasome inhibitor, pharmaceutical composition containing said combination and kit of the same